Also, the median donor ages and CD34+ count were comparable among the two cohorts (30 years vs. 33 years, p = 0.399; 8.1 × 106/kg vs. 7.4 × 106/kg, p = 0.810, respectively), Most individuals in both the ATG-T and ATG-G group were diagnosed with AML or MDS (37.5% vs. 53.2%, respectively), followed by ALL (25% vs. 17%, respectively) and lymphoma/myeloma (20% vs. 14.9%, respectively). This evidence concerns the gene CD34 and plasma cell myeloma.